美股异动 | 口服减肥药orforglipron三期试验报捷 礼来(LLY.US)一度涨超3%

Core Viewpoint - Eli Lilly's oral weight loss drug orforglipron shows superior weight maintenance effects in a Phase 3 clinical trial compared to previous injectable weight loss medications [1] Group 1: Clinical Trial Results - The ATTAIN-MAINTAIN trial demonstrated that patients switching from Wegovy or Zepbound to orforglipron maintained their weight loss achieved through injections [1] - In the 52-week study, patients transitioning from Wegovy experienced an average weight difference of 0.9 kg, while those switching from Zepbound had an average weight difference of 5.0 kg [1] - The study met its primary endpoint and all key secondary endpoints, indicating strong efficacy [1] Group 2: Safety and Tolerability - The safety and tolerability profile of orforglipron aligns with previous Phase 3 study results, confirming its safety characteristics for once-daily oral administration [1]